Member Info for shares123

Looking through the companies last presentation they warn that COVID may affect the use of core antibodies in the lab.
The Vit D antibody is 52% of revenue for example. The others are related to non-emergency thryoxine testing and fertily testing mainly. The hospitals and doctors have had non-critical use significantly reduced during the COVID crisis. I think the next set of results will show a big down turn in revenue.

I am starting to think that the demand for testing people in quarantine for Vit D levels will be greatly reduced! The virus outbreak could also affect testing of people for reproductive hormones. As fertility testing is put on hold and COVID patients are prioritised.

https://beta.companieshouse.gov.uk/company/11321836/filing-history

Did any one catch the podcast. Is there any further info available. https://www.*************.com/views/31792/tom-winnifrith-bearcast-adam-reynolds-new-departure-loopup-stinks-praise-for-the-sfo-fcr

Ahead of expectations. I am looking forward to my 10.96p per share dividend. Solid balance sheet, steady increasing dividend and EPS.

Here is a explanation of the distributable reserves in the annual report. http://www.stockopedia.com/content/small-cap-value-report-6-jan-2017-craw-zyt-g4m-165336/

"Special business resolution number five proposes that the Company undertakes a court approved capital reduction process designed to convert £8.9m of non-distributable reserves into distributable reserves." Looks like a good use of spare cash for the benefit of shareholders.

I am a little excited to see what the RTO price of Big Sofa will be midday on Monday. If NWOG gets a ok settlement in regards to the legacy issues things could work out ok.

upon Admission HubCo will reimburse NWOG with a sum of £100,000 in relation to financial, legal and other advisory costs incurred by NWOG in its abortive acquisition of Big Sofa.

On admission we get 4,280,446 New Ordinary Shares at the lower of a) the issue price of 17p or b) the lowest price at which New Ordinary Shares may be issued by the Company as part of any fundraising conducted between the date of Admission and 31 December 2018.

I think it is interesting that he is putting Big sofa into Hubco as it is a unlisted enitity like NEW now is. So it is possible if they manage a settlement to afterward do another RTO.

Ow and HubCo. got big Sofa http://www.investegate.co.uk/aim/rns/sch-1---big-sofa-technologies-group-plc/201611301530015952Q/

http://www.investegate.co.uk/new-world-oil---38--gas/rns/letter-from-jersey-financial-services-commission/201611300700114736Q/

"The Group's underlying profit (before this non-cash item) is expected to be significantly ahead of last year and at least in line with market expectations." Sounds Good.

Nice jump up today. I think it was mentioned in a penny share mag. So it could be a short term spike.

Today Winnifrith states in his podcast that he taken part in a placing that should be announced on Monday mourning. He has invested in all A.R. RTO placing todate. Is Monday going to be the placing date for New world oil?

Finncap 08:1923 Aug Bioventix* (BVXP): Earnings upgrades post trading update (CORP) Following yesterday’s positive trading statement relating to FY 2016 revenues as well as comments pertaining to its troponin antibody being developed into a diagnostic test for heart attacks by Siemens, and in which management states that it expects “to commence significant sales during FY 2018”, thus potentially mitigating the effects of lost revenues from NTproBNP antibody in FY020 18, we are upgrading forecasts for FY 2016 and FY 2017. Fully diluted EPS are forecast to be 64.9p and 71.2p in 2016 and 2017, +13% and +19% above prior estimates, respectively. We assume a FY 2016 dividend of 43p to be declared (1.5x cover), which we estimate should rise to 46p in FY 2017. Net cash at 30 June 2016 is estimated to have been £5.2m and is expected to rise to £6.3m in FY 2017. Consequently, we increase our target price by 8% to 1350p, at which level the stock would trade on FY 2017 PE and EV/EBITDA multiples of 19.0x and 14.3x, respectively, supported by a DCF valuation of 1450p.

Seems to be robust revenue growth as promised by Peter in his recent Piworld presentation. "For the next 5 years revenue growth will just continue without me doing anything because its already in the can at our customers." Matt thanks for the earning estimate and price target. Here is Leon Boris estimate just for balance. http://www.stockopedia.com/content/small-cap-value-report-22-aug-2016-bvxp-trcs-147765/?comment=18#18

Hi Matt, largest turnover from EU and USA but I guess they all pay in sterling. So the devaluation of pound makes products cheaper which may increase sales.

At this price f(PE) 16.8 and 4.2% Yield, 2.11x dividend cover this looks to be a good value high quality share. with 10% cash support for market cap and no debt. Plus, two years of EPS growth predicted by brokers (+13% and +4%). I decided to top up abit at these levels.